NeuroDerm's ND0612 introduces a pioneering approach to Parkinson's disease management with its self-administered continuous subcutaneous infusion of levodopa/carbidopa. Unlike traditional oral formulations, ND0612 bypasses the gastrointestinal tract, offering increased bioavailability and potentially more reliable relief from motor fluctuations
By providing a continuous, adjustable dose of levodopa/carbidopa via subcutaneous infusion, ND0612 aims to extend the therapeutic window for Parkinson's patients. This innovative approach seeks to minimize motor fluctuations and optimize patients' "ON" time, thereby offering greater daily-life predictability and independenc...